The less invasive method could help men avoid some of the unpleasant side effects such as urinary incontinence and sexual dysfunction, which are known deterrents for patients facing potential prostatectomy.
Synthetic images are often of diagnostic quality and can be reliably used to assess clinically significant prostate cancer while also sparing patients from contrast exposure.
Early evidence suggests a new PET imaging agent from California-based Attralus can help evaluate all varieties of systemic cardiac amyloidosis. It has now been granted the FDA's breakthrough therapy designation.
Bharath Krishnamurthy, director of health policy and analytics, American Hospital Association, explains factors leading to the economic instability of the U.S. healthcare system.
Debra Monticciolo, MD, who has previously led both the Society of Breast Imaging and the American College of Radiology, discussed how different screening strategies may impact patient outcomes.
RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.
Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.
A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.
